Lyon, February 2025
To support Edelris’s growing ambitions, we are delighted to welcome Joseph Zolnerciks as Chief Business Officer.
Joe has a proven track record in the CRO pharma and biotech industry and was for 8 years head of Business Development at SOLVO Biotechnology. After the acquisition of SOLVO by Charles River Laboratories, he led Charles River’s global DMPK and in vitro ADME Business Development team.
Joe has a Ph.D. in Membrane Protein Biochemistry from Imperial College London and completed post-doctoral positions at the University of Washington (Profs. Unadkat & Atkins, Depts. of Pharmaceutics and Medicinal Chemistry), at Queen Mary University of London (Prof. Linton), and the Biozentrum, University of Basel (Prof. A. Seelig).
Joe’s profound knowledge of the market considerably strengthens Edelris’s leadership in servicing our clients with our quality solutions for early small-molecule drug development.
More news
About Edelris
Expanding the boundaries for your small molecule drug discovery!
Edelris is a leading Drug Discovery CRO, providing Compound Libraries, Organic & Medicinal Chemistry, High Throughput Screening, and Analytical expert services to the Pharmaceutical, Cosmetic, Crop Protection, and Biotech sectors.
Cross-fertilizing our combined experiences, knowledge, and techniques, together we break through to successful solutions for you.